17,261 trials
Japanese Encephalitis · Yellow Fever
Primary: Number of Participants With Japanese Encephalitis Seroconversion Following ChimeriVax™-JE or STAMARIL® Alone or the Co-administration of ChimeriVax™-JE and STAMARIL®, or…
Adult Favorable Prognosis Hodgkin Lymphoma · Adult Lymphocyte Depletion Hodgkin Lymphoma · Adult Lymphocyte Predominant Hodgkin Lymphoma
Primary: Assess Number of Patients Who Achieve Confirmed and Unconfirmed Complete Response (CR) or Partial Response (PR) — 0; 1; 0; 0 participants
Stomach Neoplasms
Primary: Percentage of Participants With Overall Response Rate (ORR) Based on Modified Response Evaluation Criteria in Solid Tumors (RECIST) — 15.4 percentage of participants
Recurrent Adult Burkitt Lymphoma · Recurrent Adult Diffuse Large Cell Lymphoma
Primary: Assess Number of Patients Who Achieve Confirmed and Unconfirmed Complete Response (CR) or Partial Response (PR) — 0; 0; 0; 20 participants
Influenza
Primary: To Demonstrate the Equivalence of Antibody Response Against A/H5N1 Strain Elicited by the Three Different Immunization Schedules on Day 43. — 4.64; 4.10; 4.61; 14 Area…
Ischemic Stroke
Primary: Symptomatic and Radiographic Intracerebral Hemorrhage — 6.2 percentage of patients
Extensive Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: Objective Response (Confirmed and Unconfirmed, Complete and Partial Responses Per RECIST) — 11; 2 percentage of participants
Meningococcal Disease
Primary: Percentage of Subjects With hSBA ≥1:8 — 27; 8; 29; 3 Percentages of subjects
HIV · HIV Infections
Primary: Combined HIV/STI 12-month Incidence Rates of HIV, Syphilis, Chlamydia, Gonorrhea and Trichomonas Vaginalis. — 65.02; 67.66; 35.02; 54.04 incidence density per 100 person…
Relapsed or Refractory Lymphoproliferative Malignancies · Hodgkin's Lymphoma · Peripheral T-cell Lymphoma
Primary: Objective Responses Assessed by International Workshop Criteria (IWC) — 8; 5; 7 participants
Neurofibroma, Plexiform · Neurofibromatosis Type I
Primary: Median Time to Progression — 10.6; 14.5; 19.2; 13.3 Months
Multiple Myeloma
Primary: Participants With Dose Limiting Toxicity (DLT) — 0; 0; 0 participants
Breast Cancer
Primary: Cardiac Safety - Number of Participants With Grade 3-4 Clinical Congestive Heart Failure (CHF) — 1; 3; 1 participants
Alpha-1 Antitrypsin Deficiency
Primary: Frequency of Grade 3 or 4 Adverse Events — 0; 0; 1 participants
HIV-1 and Hepatitis C Co-Infection
Primary: The Proportion of All Subjects With HCV Viral Load < 60 IU/mL at Week 24 of Step 2. — 0.158 proportion of participants — p=0.29